Researchers supported by the National Institutes of Health have created a new framework for one of aging biology’s most difficult puzzles, where senescent cells appear in the body and how they differ from place to place. In an NIH announcement, the agency said a research consortium has produced the first comprehensive atlas of these cells across human tissues, with a compendium of papers published in the June 11 issue of Cell.
The work comes from the NIH Common Fund’s Cellular Senescence Network, also known as SenNet. The program was launched in 2021 to identify and characterize cells that have stopped dividing yet remain biologically active. These cells are rare, varied and deeply shaped by their surroundings, which has made them hard to catalog in a systematic way.
SenNet researchers are now organizing these cells into “senotypes,” a classification system based on where the cells are found and the conditions around them. The goal is to give scientists a clearer map of cellular senescence across the lifespan and eventually a better way to design therapies for diseases linked to aging.
A New Map of Senescent Cells
Aging tissues contain small populations of senescent cells that can change the behavior of nearby cells. Until now, researchers have had limited tools for seeing how these cells vary across organs, disease states and age. The new SenNet atlas is meant to provide a shared reference for that work.
The atlas charts senescent cells in human tissues from several parts of the body. NIH highlighted the brain prefrontal cortex, lungs and lymph nodes among the areas included in the latest research. Each tissue presents a different biological setting, which matters because senescent cells can behave differently depending on where they arise.
Scientists have long known that cellular senescence involves a stop in cell division. That stop can protect the body in some contexts, especially when a damaged cell could otherwise keep multiplying. The challenge is that senescent cells remain metabolically active and their signals can influence inflammation, tissue repair and disease risk.
By building a large-scale map, SenNet gives researchers a way to compare these cells across tissues rather than treating them as a single uniform category. That comparison could help separate patterns linked to normal repair from patterns associated with harmful accumulation during aging.
Why These Cells Matter in Aging
Senescent cells play a complicated role in the body. In healthy tissue, they can support wound healing and help prevent tumor growth by halting the division of damaged cells. The immune system usually clears them after they’ve served their purpose.
With age, that cleanup process can weaken. When senescent cells build up, they can release signals that contribute to chronic inflammation and other biological changes associated with age-related disease. This accumulation has made cellular senescence a major focus in aging research.
The NIH announcement describes senescent cells as active cells that stop dividing but stay present in the body. That simple definition hides a great deal of variation. A senescent cell in lung tissue may have different features from one in a lymph node and a cell in a healthy tissue may differ from one in a disease setting.
This is why the new atlas matters. It gives researchers a more precise way to ask where senescent cells appear, what features identify them and which signals they send to surrounding tissue. Those questions are central to understanding whether a future therapy should remove certain cells, quiet their harmful signals, or preserve their useful functions.
The Senotype Framework
The key conceptual advance in the new work is the senotype framework. SenNet researchers use the term senotypes to describe categories of senescent cells based on tissue location and surrounding conditions. The framework reflects a basic finding from the consortium, senescent cells can differ widely across the human body.
That matters for therapy development. A broad treatment that affects many senescent cells could have mixed results if some of those cells are helping tissue repair or suppressing tumor growth. A more refined classification system could help researchers focus on cell states that are more likely to cause harm.
“This knowledge could help researchers move toward more targeted therapies that focus on harmful cells while preserving beneficial ones,” said Nicole Kleinstreuer, Ph.D., NIH Deputy Director for Program Coordination, Planning and Strategic Initiatives, who leads the NIH Common Fund.
The senotype idea also gives scientists a shared language. Aging research often brings together cell biology, immunology, computational science, pathology and clinical studies. A common framework can help those fields compare findings and build compatible datasets.
SenNet’s approach also recognizes the importance of context. Tissue type, health status and local environment all influence how a cell enters or maintains senescence. The atlas is designed to capture that diversity rather than flatten it into a single signature.
Signals Found in Blood
One of the most promising parts of the SenNet effort involves biomarkers. According to NIH, the consortium developed computational tools to identify distinctive biological features of senescent cells. Those tools helped researchers find markers in blood linked to important aging-related outcomes.
The highlighted markers can predict kidney disease, frailty and future diabetes risk in human aging studies. These findings are early steps toward practical clinical uses, because blood tests are far easier to collect than tissue samples from organs such as the brain or lungs.
Blood biomarkers could eventually help researchers track cellular senescence in living people over time. That would be valuable for testing whether a treatment changes senescent cell activity, or whether certain senescence patterns appear before disease symptoms become obvious.
Care is still needed when interpreting these signals. A marker associated with risk can guide research, but it does not automatically become a diagnostic test or a treatment target. The SenNet work gives scientists candidates to investigate further in larger and more specific studies.
Even so, blood-based clues are an important bridge between deep tissue mapping and clinical research. They could help connect the cell-level atlas to outcomes that doctors and patients care about, such as frailty, kidney function and metabolic disease risk.
New Tools for Rare Cells
Senescent cells are difficult to study partly because they can be rare within a tissue. A tiny population may still have a strong effect if it releases powerful signals into its surroundings. Finding those cells requires methods that can examine tissue in fine detail.
The NIH announcement points to advances in single-cell methods, spatial omics and AI-based methods. Single-cell approaches allow researchers to examine individual cells instead of averaging signals across a whole tissue sample. Spatial methods add another layer by showing where those cells sit inside tissue architecture.
That location is crucial. A senescent cell near immune cells, blood vessels, or damaged tissue may behave differently from one surrounded by healthy neighbors. Spatial maps can help researchers connect a cell’s molecular profile with its physical neighborhood.
Artificial intelligence and computational tools are also central to the project. Large tissue maps can contain enormous amounts of data and senescent cells may lack one universal marker that identifies them in every tissue. Algorithms can help detect patterns that would be hard to see by manual inspection alone.
These technologies are part of the reason SenNet can attempt a body-wide atlas now. The field has moved beyond looking for one simple sign of senescence. Researchers can now combine many features, including gene activity, cell location, tissue context and disease status.
A Path Toward Targeted Aging Therapies
The atlas also points toward future therapeutic work. NIH highlighted possible applications in disease research and the early testing of senolytics, experimental drugs designed to selectively eliminate senescent cells. These therapies remain an active research area and the new framework could help identify which senescent cells should be targeted.
Precision will be important. Since senescent cells can support wound healing and help block tumor growth, researchers need ways to distinguish harmful senescent cell states from beneficial ones. The senotype framework could help provide that needed separation.
SenNet’s public atlases may also help scientists study many age-related diseases through a shared resource. The program is supported by multiple NIH Institutes and Centers, with leadership from the National Institute on Aging and the National Cancer Institute. That structure reflects the broad relevance of senescence across aging, cancer biology, tissue repair and chronic disease.
The current work should be viewed as a foundation. It maps cellular states and proposes a classification system, while future studies will need to test how specific senotypes influence disease and treatment responses. The atlas gives researchers a starting point for those experiments.
For aging science, the advance is both practical and conceptual. A rare group of cells that once seemed difficult to pin down is being mapped across human tissues with new tools and a shared vocabulary. That map could help turn cellular senescence into a more precise target for understanding health across the human lifespan.
